| Company | Date | Position | Consensus ⓘ | Price Target ⓘ | 2-Yr Return |
|---|---|---|---|---|---|
|
HDLMY
Heidelberg Materials AG ADR
|
Nov 06, 2025 | BUY |
Strong Buy
+16.8% avg upside
2 analysts
|
$49.00
16.32% Upside
|
-5.3% |
|
GB:HIK
Hikma Pharmaceuticals
|
Oct 16, 2025 | BUY |
Strong Buy
+54.6% avg upside
8 analysts
|
$2510.00
68.88% Upside
|
· |
|
GB:SPI
Spire Healthcare
|
Jul 31, 2025 | BUY |
Strong Buy
+36.4% avg upside
6 analysts
|
$280.00
30.03% Upside
|
· |
|
GB:0HNZ
Fagron SA
|
Jun 26, 2025 | BUY |
Buy
-8.2% avg upside
5 analysts
|
$22.70
5.64% Downside
|
· |
|
CH:STMN
Straumann Holding AG
|
Jun 25, 2025 | BUY |
Buy
+23.6% avg upside
14 analysts
|
$145.00
37.64% Upside
|
· |
|
CH:SDZ
Sandoz Group Ltd
|
Jun 24, 2025 | HOLD |
Buy
-5.6% avg upside
11 analysts
|
$41.00
41.05% Downside
|
· |
|
DE:FME
Fresenius Medical Care AG & Co. KGaA
|
Jun 24, 2025 | BUY |
Hold
+23.2% avg upside
22 analysts
|
$60.00
45.54% Upside
|
· |
|
FMS
Fresenius Medical Care
|
Jun 20, 2025 | BUY |
Hold
+81.1% avg upside
14 analysts
|
$34.50
47.47% Upside
|
-20.3% |
|
DE:GXI
Gerresheimer
|
Jun 03, 2025 | HOLD |
Buy
+128.4% avg upside
15 analysts
|
$55.00
112.31% Upside
|
· |
|
DE:FRE
Fresenius SE & Co. KGaA
|
May 29, 2025 | BUY |
Strong Buy
+28.7% avg upside
20 analysts
|
$50.00
26.47% Upside
|
· |
|
RGEDF
Chemical Works of Gedeon Richter
|
May 13, 2025 | BUY |
Strong Buy
+11.3% avg upside
3 analysts
|
$40.20
5.30% Upside
|
+62.9% |
|
SDZNY
Sandoz Group Ltd Sponsored ADR
|
May 17, 2024 | BUY |
Buy
-50.0% avg upside
2 analysts
|
$47.00
45.30% Downside
|
+153.3% |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.